ARROWHEAD PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.71 per share for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2012-08-13
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2012-06-30 was -$0.71.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2012-03-31 was -$0.50.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-06-30 was -$0.24.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-03-31 was -$0.11.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for fiscal 2011 was -$1.08.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for fiscal 2010 was -$0.49.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|---|---|
| 2012-06-30 | -$0.71 10-Q · filed 2012-08-13 | -$1.48 10-Q · filed 2012-08-13 | ||||
| 2012-03-31 | -$0.50 10-Q · filed 2012-05-08 | -$0.75 10-Q · filed 2012-05-08 | ||||
| 2011-09-30 | -$1.08 10-K · filed 2011-12-20 | |||||
| 2011-06-30 | -$0.24 10-Q · filed 2012-08-13 | -$0.03 10-Q · filed 2011-08-08 | -$0.71 10-Q · filed 2012-08-13 | -$0.07 10-Q · filed 2011-08-08 | ||
| 2011-03-31 | -$0.11 10-Q · filed 2012-05-08 | -$0.49 10-Q · filed 2012-05-08 | ||||
| 2010-09-30 | -$0.49 10-K · filed 2011-12-20 | |||||
| 2010-06-30 | -$0.03 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |